Recent headlines from the sources AlphaScala monitors. AlphaScala analysis is published in the main market section.
Allstate's underwriting margins are improving, but slow auto premium growth keeps the stock range-bound. Watch for a catalyst to break this stagnation.
Rising customer acquisition costs could squeeze STRA operating margins as AI-driven search tools reduce traditional website traffic and lead efficiency.
The fintech pioneer is stepping back from the firm he launched in 2018 to pursue new ventures. Investors must now watch if the company retains market share.
Operations continued for over 60 minutes after a worker died on-site, sparking safety scrutiny. Watch for potential OSHA probes and rising labor tensions.
Market overreaction to housing sector headwinds creates a buying opportunity for FNF. Analysts expect a 13% rebound as dividend stability drives recovery.
The integration of ShopBack Pay into 365pay POS systems removes manual reward entry. Watch for Q3 2026 adoption rates to gauge impact on repeat dining traffic.
Developers gain full access to the M2.7 architecture at $0 cost. Widespread adoption could force a pricing shift among competitors charging for AI access.
Systematic RC drilling at the Kalgoorlie project follows an 18-month exploration strategy. Investors should watch for upcoming drill core assay results.
Surging oil prices are squeezing corporate margins and fueling market anxiety. Investors must monitor energy costs as the primary indicator for stability.
Developers are pivoting from niche projects to integrated communities in Gift City, signaling a shift toward long-term revenue streams for the sector.
Filter out market noise by applying a three-step valuation framework. Use five years of historical data to identify mispriced stocks and build a safety margin.
Operational milestones and a $50 million R&D allocation signal long-term scalability. Watch for revenue growth confirmation in the November audited report.
The state-owned insurer will double the number of shares in circulation to boost liquidity. Investors now await the official record date for distribution.
Rio Tinto's low gearing and consistent dividends attract value investors. With an Alpha Score of 62, watch for shifts in global iron ore demand and pricing.
Markets are betting corporate earnings will outpace rising energy prices. Watch upcoming inflation data for signs the equity-bond disconnect will close.
Stronger-than-expected Q4 revenue and improved cash flow signal a successful turnaround. Watch for sustained growth to support ongoing share buybacks.
SiteSell is removing upfront financial pressure for entrepreneurs by allowing a full 90-day trial. Monitor churn rates to gauge long-term revenue viability.
Identify valuation gaps in 12 overlooked assets, including ZS and DVN, where operational momentum suggests significant upside as institutional interest grows.
The agreement for G-Series industrial blowers includes an initial AU$71,000 order. Scaling minimums aim to provide long-term revenue visibility in South Asia.
Wedgewood Partners outperformed by leaning on TSM and MSFT as essential AI infrastructure. Watch capital expenditure trends to gauge future growth durability.
Travere Therapeutics secures the first and only approved medicine for FSGS, shifting focus to commercial launch and patient access to drive revenue growth.
Eurofins Scientific pairs 6.5% organic growth with a 2% dividend yield. This defensive strategy aims to anchor portfolios against high-beta market volatility.
Geopolitical tensions in the Middle East drove the fund's quarterly decline. Investors must now weigh if this dip signals a shift toward defensive positioning.
Justdial net profit climbed to $58M as BharatPe faces leadership instability. Investors are now watching for executive replacements and long-term roadmaps.
Hackers bypassed security via analytics firm Anodot to access Snowflake data. Investors must now weigh potential legal liabilities and rising compliance costs.
FILSPARI marks a shift for Travere Therapeutics from development to commercialization. Watch physician adoption rates to gauge the drug's revenue trajectory.
Macquarie offers cyclical exposure to capital markets while Coles provides defensive retail stability. Weigh these distinct risk profiles for 2026 portfolios.
Mainboard listings are struggling as retail participation hits multi-year lows. Expect issuers to slash premium valuations to lure traders back to the market.
Entropy Neurodynamics confirmed repeatable psychedelic effects for TRP-8803. New R&D incentives extend the cash runway as Cohort 2 enrollment remains on track.
The Dow Jones climbed 0.6% as investors track high-volume activity in BE. Watch for follow-through volume in CRDO to determine if this rally is sustainable.